Shanghai Shenqi Pharmaceutical Investment Management

Shanghai Shenqi Pharmaceutical Investment Management is a primary subsidiary and investment vehicle for Guizhou Shenqi Pharmaceutical, a major Chinese pharmaceutical group listed on the Shanghai Stock Exchange. The company specializes in the development, manufacturing, and investment management of Traditional Chinese Medicine (TCM) and modern pharmaceutical products. Its core portfolio is heavily weighted toward oncology-supportive care, cardiovascular health, and orthopedics. The firm's most recognized product, Shenqi Fuzheng Injection, is a widely utilized adjunctive therapy in China for cancer patients undergoing chemotherapy to enhance immune function. Through its strategic management of pharmaceutical assets, the company maintains a comprehensive presence across the research, production, and commercial distribution sectors of the Chinese healthcare market.